2004 Annual Meeting | Neuromuscular Therapy
| 07:00 PM - 07:35 PM | Clinical Approach to the Management of the Muscular Dystrophies John T. Kissel, MD, FAAN | |
| 07:35 PM - 08:10 PM | Clinical Approach to the Management of ALS Carlayne E. Jackson, MD, FAAN | |
| 08:10 PM - 08:45 PM | What We Can Do When There is Nothing More We Can Do:  The Role of Palliative Care Robert M. Taylor, MD, FAAN | |
| 08:45 PM - 09:00 PM | Questions and Answers | 
| John T. Kissel, MD, FAAN | Dr. Kissel has nothing to disclose. | 
| Carlayne E. Jackson, MD, FAAN | Dr. Jackson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Mitsubishi Tanabe Pharma America. Dr. Jackson has received personal compensation in the range of $100,000-$499,999 for serving as an officer or member of the Board of Directors for AAN. The institution of Dr. Jackson has received research support from NIH. The institution of Dr. Jackson has received research support from Massachussetts General Hospital. | 
| No disclosure on file | |
| Robert M. Taylor, MD, FAAN | No disclosure on file |